Published in Gynecol Oncol on March 13, 2007
Cancer survivorship research: the challenge of recruiting adult long term cancer survivors from a cooperative clinical trials group. J Cancer Surviv (2009) 1.04
Chronic physical effects and health care utilization in long-term ovarian germ cell tumor survivors: a Gynecologic Oncology Group study. J Clin Oncol (2009) 0.87
Molecular characteristics of malignant ovarian germ cell tumors and comparison with testicular counterparts: implications for pathogenesis. Endocr Rev (2013) 0.85
Issues of ovarian cancer survivors in the USA: a literature review. Support Care Cancer (2013) 0.81
Nursing research in the Gynecologic Oncology Group. Semin Oncol Nurs (2013) 0.80
Predictors of psychosocial adjustment during the postradiation treatment transition. West J Nurs Res (2010) 0.79
Fertility preservation in women with cervical, endometrial or ovarian cancers. Gynecol Oncol Res Pract (2016) 0.78
The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care (1992) 144.02
Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol (1988) 60.71
The Posttraumatic Growth Inventory: measuring the positive legacy of trauma. J Trauma Stress (1996) 7.34
Measuring spiritual well-being in people with cancer: the functional assessment of chronic illness therapy--Spiritual Well-being Scale (FACIT-Sp). Ann Behav Med (2002) 5.69
The validity and relative precision of MOS short- and long-form health status scales and Dartmouth COOP charts. Results from the Medical Outcomes Study. Med Care (1992) 4.58
The Duke-UNC Functional Social Support Questionnaire. Measurement of social support in family medicine patients. Med Care (1988) 3.85
Validity and reliability of the family APGAR as a test of family function. J Fam Pract (1982) 2.27
Quality of life among younger women with breast cancer. J Clin Oncol (2005) 2.19
No evidence of acute cardiovascular complications of chemotherapy for testicular cancer: an analysis of the Testicular Cancer Intergroup Study. J Clin Oncol (1992) 2.11
Factors influencing quality of life in cancer patients: anemia and fatigue. Semin Oncol (1998) 2.05
The Sexual Activity Questionnaire: a measure of women's sexual functioning. Qual Life Res (1996) 1.85
Defining and measuring reproductive concerns of female cancer survivors. J Natl Cancer Inst Monogr (2005) 1.70
Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin: a trial of the Gynecologic Oncology Group. J Clin Oncol (1994) 1.68
Is there a cost to poor communication in cancer care?: a critical review of the literature. Psychooncology (2005) 1.60
What do we know about facilitating patient communication in the cancer care setting? Psychooncology (2005) 1.47
Group coping skills instruction and supportive group therapy for cancer patients: a comparison of strategies. J Consult Clin Psychol (1986) 1.46
Age at diagnosis and quality of life in breast cancer survivors. Cancer Pract (2002) 1.32
Evaluation of long-term toxicity after chemotherapy for testicular cancer. J Clin Oncol (1996) 1.29
Psychological adjustment to survival from Hodgkin's disease. J Consult Clin Psychol (1986) 1.28
A relationship between perceived self-efficacy and quality of life in cancer patients. Patient Educ Couns (1991) 1.24
Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide, and cisplatin. J Clin Oncol (1990) 1.16
Quality of life in breast cancer survivors as identified by focus groups. Psychooncology (1997) 1.09
Schemas, sexuality, and romantic attachment. J Pers Soc Psychol (1998) 1.07
Late effects of treatment for germ cell tumors during childhood and adolescence. J Pediatr Hematol Oncol (1999) 0.98
Developing communication competency in the context of cancer: a critical interpretive analysis of provider training programs. Psychooncology (2005) 0.89
Cisplatin, vinblastine, and bleomycin in advanced and recurrent ovarian germ-cell tumors. A trial of the Gynecologic Oncology Group. Ann Intern Med (1989) 0.88
Adjuvant therapy of completely resected dysgerminoma with carboplatin and etoposide: a trial of the Gynecologic Oncology Group. Gynecol Oncol (2004) 0.84
Quality of life as a cancer nursing outcome variable. NLN Publ (1987) 0.79
Predictors of quality of life among long-term survivors of gestational trophoblastic disease. J Reprod Med (2004) 0.78
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med (2007) 20.19
Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med (2006) 13.63
Psychometric evaluation and calibration of health-related quality of life item banks: plans for the Patient-Reported Outcomes Measurement Information System (PROMIS). Med Care (2007) 12.71
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet (2011) 12.13
Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med (2013) 10.74
Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. Ann Intern Med (2007) 9.05
Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med (2011) 8.93
Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain (2007) 8.89
Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol (2003) 8.31
A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol (2004) 8.29
Effects of Testosterone Treatment in Older Men. N Engl J Med (2016) 6.66
Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. J Clin Oncol (2014) 6.64
High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med (2007) 6.42
Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol (2007) 6.24
Measuring spiritual well-being in people with cancer: the functional assessment of chronic illness therapy--Spiritual Well-being Scale (FACIT-Sp). Ann Behav Med (2002) 5.69
The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation. Health Qual Life Outcomes (2003) 5.58
Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol (2011) 5.43
Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol (2002) 4.69
Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol (2004) 4.69
Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet (2006) 4.26
Item banks for measuring emotional distress from the Patient-Reported Outcomes Measurement Information System (PROMIS®): depression, anxiety, and anger. Assessment (2011) 4.21
Representativeness of the Patient-Reported Outcomes Measurement Information System Internet panel. J Clin Epidemiol (2010) 4.18
Measuring health-related quality of life in patients with hepatobiliary cancers: the functional assessment of cancer therapy-hepatobiliary questionnaire. J Clin Oncol (2002) 4.16
Development of physical and mental health summary scores from the patient-reported outcomes measurement information system (PROMIS) global items. Qual Life Res (2009) 4.13
Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol (2004) 3.85
Recommendations on evidence needed to support measurement equivalence between electronic and paper-based patient-reported outcome (PRO) measures: ISPOR ePRO Good Research Practices Task Force report. Value Health (2008) 3.68
Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes (2007) 3.66
Prospective, observational study of pain and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or prostate cancer. J Clin Oncol (2012) 3.65
Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol (2012) 3.65
Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 3.65
Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol (2004) 3.57
Routine offer of antenatal HIV testing ("opt-out" approach) to prevent mother-to-child transmission of HIV in urban Zimbabwe. Bull World Health Organ (2007) 3.51
Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. J Clin Oncol (2013) 3.48
Derivation and Validation of a Scoring System to Stratify Risk for Advanced Colorectal Neoplasia in Asymptomatic Adults: A Cross-sectional Study. Ann Intern Med (2015) 3.45
A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Eval Health Prof (2005) 3.43
Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol (2006) 3.39
Assessment of neurological and behavioural function: the NIH Toolbox. Lancet Neurol (2010) 3.20
Item response theory analyses of physical functioning items in the medical outcomes study. Med Care (2007) 3.10
Clinical significance of patient-reported questionnaire data: another step toward consensus. J Clin Epidemiol (2005) 2.98
Standardizing patient-reported outcomes assessment in cancer clinical trials: a patient-reported outcomes measurement information system initiative. J Clin Oncol (2007) 2.97
Development of a PROMIS item bank to measure pain interference. Pain (2010) 2.85
Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol (2009) 2.82
Prevention of mother to child transmission of HIV: evaluation of a pilot programme in a district hospital in rural Zimbabwe. BMJ (2004) 2.68
Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol (2007) 2.63
Efficiency of static and computer adaptive short forms compared to full-length measures of depressive symptoms. Qual Life Res (2009) 2.55
General population and cancer patient norms for the Functional Assessment of Cancer Therapy-General (FACT-G). Eval Health Prof (2005) 2.51
Responsiveness and minimal important differences for patient reported outcomes. Health Qual Life Outcomes (2006) 2.48
Identifying important outcome domains for chronic pain clinical trials: an IMMPACT survey of people with pain. Pain (2007) 2.47
Randomized, controlled trial of an easy-to-read informed consent statement for clinical trial participation: a study of the Eastern Cooperative Oncology Group. J Clin Oncol (2003) 2.41
Progress in assessing physical function in arthritis: PROMIS short forms and computerized adaptive testing. J Rheumatol (2009) 2.39
Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. Lancet Oncol (2008) 2.34
Item banking to improve, shorten and computerize self-reported fatigue: an illustration of steps to create a core item bank from the FACIT-Fatigue Scale. Qual Life Res (2003) 2.32
Implementing a rural programme of prevention of mother-to-child transmission of HIV in Zimbabwe: first 18 months of experience. Trop Med Int Health (2004) 2.30
Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. Clin Cancer Res (2005) 2.29
Are inflammatory cytokines the common link between cancer-associated cachexia and depression? J Support Oncol (2005) 2.27
Minimally important differences were estimated for six Patient-Reported Outcomes Measurement Information System-Cancer scales in advanced-stage cancer patients. J Clin Epidemiol (2011) 2.24
Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. J Clin Oncol (2007) 2.24
Evaluating equivalency between response systems: application of the Rasch model to a 3-level and 5-level EQ-5D. Med Care (2007) 2.22
Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst (2002) 2.19
Relative to the general US population, chronic diseases are associated with poorer health-related quality of life as measured by the Patient-Reported Outcomes Measurement Information System (PROMIS). J Clin Epidemiol (2010) 2.19
Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer (2002) 2.17
A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale. J Clin Epidemiol (2004) 2.14
Predicting EuroQol (EQ-5D) scores from the patient-reported outcomes measurement information system (PROMIS) global items and domain item banks in a United States sample. Qual Life Res (2009) 2.10
Quality of life of patients with endometrial cancer undergoing laparoscopic international federation of gynecology and obstetrics staging compared with laparotomy: a Gynecologic Oncology Group study. J Clin Oncol (2009) 2.08
Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med (2004) 2.06
Neuro-QOL: quality of life item banks for adults with neurological disorders: item development and calibrations based upon clinical and general population testing. Qual Life Res (2011) 1.97
Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group. Gynecol Oncol (2003) 1.97
ISOQOL recommends minimum standards for patient-reported outcome measures used in patient-centered outcomes and comparative effectiveness research. Qual Life Res (2013) 1.96
Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. J Clin Oncol (2004) 1.95
Symptoms and treatment burden associated with cancer treatment: results from a cross-sectional national survey in the U.S. Support Care Cancer (2008) 1.89
Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol (2007) 1.88
Issues in the development of an item bank. Arch Phys Med Rehabil (2003) 1.87
The use of PROMIS and assessment center to deliver patient-reported outcome measures in clinical research. J Appl Meas (2010) 1.87
Psychometric comparison of the standard EQ-5D to a 5 level version in cancer patients. Med Care (2007) 1.87
Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension. Hypertension (2005) 1.85
Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells. J Pharmacol Exp Ther (2006) 1.84
Chronic anemia and fatigue in elderly patients: results of a randomized, double-blind, placebo-controlled, crossover exploratory study with epoetin alfa. J Am Geriatr Soc (2007) 1.79
Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol (2007) 1.77
Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol (2005) 1.76
Factor analysis techniques for assessing sufficient unidimensionality of cancer related fatigue. Qual Life Res (2006) 1.70
Defining and measuring reproductive concerns of female cancer survivors. J Natl Cancer Inst Monogr (2005) 1.70
Late effects of cancer and hematopoietic stem-cell transplantation on spouses or partners compared with survivors and survivor-matched controls. J Clin Oncol (2007) 1.70
Using focus groups to inform the Neuro-QOL measurement tool: exploring patient-centered, health-related quality of life concepts across neurological conditions. J Neurosci Nurs (2007) 1.70
Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group Study. J Clin Oncol (2005) 1.69
Intracerebral hemorrhage and delirium symptoms. Length of stay, function, and quality of life in a 114-patient cohort. Am J Respir Crit Care Med (2013) 1.68
Content validity of patient-reported outcome measures: perspectives from a PROMIS meeting. Qual Life Res (2011) 1.68
An item response theory-based pain item bank can enhance measurement precision. J Pain Symptom Manage (2005) 1.68
The talking touchscreen: a new approach to outcomes assessment in low literacy. Psychooncology (2004) 1.67
Validity of two new patient-reported outcome measures in systemic sclerosis: Patient-Reported Outcomes Measurement Information System 29-item Health Profile and Functional Assessment of Chronic Illness Therapy-Dyspnea short form. Arthritis Care Res (Hoboken) (2011) 1.67
Site-specific interventions to improve prevention of mother-to-child transmission of human immunodeficiency virus programs in less developed settings. Am J Obstet Gynecol (2007) 1.66
Resilience, reflection, and residual stress in ovarian cancer survivorship: a gynecologic oncology group study. Psychooncology (2002) 1.64
How item banks and their application can influence measurement practice in rehabilitation medicine: a PROMIS fatigue item bank example. Arch Phys Med Rehabil (2011) 1.64
Measuring stigma across neurological conditions: the development of the stigma scale for chronic illness (SSCI). Qual Life Res (2009) 1.63
Use of a single-item screening tool to detect clinically significant fatigue, pain, distress, and anorexia in ambulatory cancer practice. J Pain Symptom Manage (2007) 1.62